Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 4/2013

01-08-2013 | Original Article

Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement

Authors: Giacomo Novara, Andrea Tubaro, Roberto Sanseverino, Sebastiano Spatafora, Walter Artibani, Filiberto Zattoni, Francesco Montorsi, Christopher R. Chapple

Published in: World Journal of Urology | Issue 4/2013

Login to get access

Abstract

Purpose

To perform a systematic review and meta-analysis of randomized clinical trials (RCTs) reporting the efficacy and safety of silodosin in the treatment of non-neurogenic male LUTS suggestive of benign prostatic enlargement.

Patients and methods

A systematic review searching multiple dataset for the term “silodosin”. A meta-analysis was conducted using Review Manager software (Cochrane Collaboration, Oxford, UK).

Results

Our systematic search retrieved four studies summarizing the data of five RCTs. Silodosin was more effective than placebo with regard to mean change in all the parameters related to the IPSS and Qmax (all p values <0.0003). Adverse events (AE), abnormal ejaculation (AEj), and withdrawal due to AE were all more common with silodosin (all p values <0.001). The prevalence of dizziness and adverse events other than AEj was similar with silodosin and placebo. Silodosin was more effective than tamsulosin 0.2 mg with regard to some IPSS-related parameters and Qmax (p ≤ 0.05). Silodosin and tamsulosin 0.4 mg were similarly effective in all the efficacy analyses. AEj was less common with tamsulosin 0.2 and 0.4 mg (p values <0.00001); adverse events other than AEj were more common with tamsulosin 0.2 and 0.4 mg (p values ≤0.05).

Conclusions

Silodosin was significantly more effective than placebo and tamsulosin 0.2 mg in improving symptoms and as effective as tamsulosin 0.4 mg. With regard to adverse events, AEj was more common with silodosin. All the adverse events other than AEj were significantly more common with tamsulosin 0.2 and 0.4 mg and as frequent with silodosin and placebo.
Appendix
Available only for authorised users
Literature
1.
Armstrong N, Vale L, Deverill M et al (2009) Surgical treatments for men with benign prostatic enlargement: cost effectiveness study. BMJ 338:b1288PubMedCrossRef
2.
Boyle P, Robertson C, Mazzetta C et al (2003) The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 92:409–414PubMedCrossRef
3.
4.
McVary KT, Roehrborn CG, Avins AL et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185(5):1793–1803PubMedCrossRef
5.
Cornu JN, Cussenot O, Haab F, Lukacs B (2010) A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 58:450–456PubMedCrossRef
6.
7.
8.
Schilit S, Benzeroual KE (2009) Silodosin: a selective α1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin Ther 31:2489–2502PubMedCrossRef
9.
Schwinn DA (2001) The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 88(suppl 2):27–34PubMedCrossRef
10.
Kawabe K (1998) Current status of research on prostate-selective alpha 1-antagonists. Br J Urol 81(suppl 1):48–50PubMed
11.
Shibata K, Foglar R, Horie K et al (1995) KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 48:250–258PubMed
12.
Andersson K-E, Lepor H, Wyllie MG (1997) Prostatic a1-adrenoceptors and uroselectivity. Prostate 30:202–215PubMedCrossRef
13.
Chapple C, Artibani W, Berges R, et al (2006) New medical developments in the management of LUTS in adult men. In male lower urinary tract dysfunction. Evaluation and management. In: McConnell, Abrams P, Denis L, Khoury S, Roehrborn C (eds) Proceedings of the 6th international consultation on new developments in prostate cancer and prostate diseases, pp 143–194
14.
15.
Jadad AR (1998) Randomised controlled trials. BMJ Publishing Group, London
16.
Rothstein HR, Sutton AJ, Borenstein M (2005) Publication bias in meta-analysis: prevention, assessment and adjustment. John Wiley, ChichesterCrossRef
17.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269PubMedCrossRef
18.
Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study Group (2006) Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98:1019–1024PubMedCrossRef
19.
Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G (2009) Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 181:2634–2640PubMedCrossRef
20.
Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E, On behalf of the European Silodosin Study Group (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo and active-controlled clinical trial performed in Europe. Eur Urol 59:342–352PubMedCrossRef
21.
Yu HJ, Lin ATL, Yang SSD et al (2011) Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int 108:1843–1848PubMedCrossRef
22.
McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398PubMedCrossRef
23.
Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57:123–131PubMedCrossRef
24.
25.
Nickel JC, Sander S, Moon TD (2008) A meta-analysis of the vascular-related safety profile and efficacy of a-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 62(10):1547–1559PubMedCrossRef
26.
Curran MP (2011) Silodosin. Treatment of the signs and symptoms of benign prostatic hyperplasia. Drugs 71(7):897–907PubMedCrossRef
27.
MacDiarmid SA, Hill L, Volinn W, Hoel G (2010) Lack of pharmacodynamics interaction of silodosin, a highly selective a1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology 75:520–525PubMedCrossRef
28.
Homma Y, Kawabe K, Takeda M, Yoshida M (2010) Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 76(6):1446–1450PubMedCrossRef
29.
Roehrborn CG, Kaplan SA, Lepor H, Volinn W (2011) Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis 14(2):143–148PubMedCrossRef
30.
Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G (2009) Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 74(6):1318–1322PubMedCrossRef
Metadata
Title
Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement
Authors
Giacomo Novara
Andrea Tubaro
Roberto Sanseverino
Sebastiano Spatafora
Walter Artibani
Filiberto Zattoni
Francesco Montorsi
Christopher R. Chapple
Publication date
01-08-2013
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 4/2013
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-012-0944-8

Other articles of this Issue 4/2013

World Journal of Urology 4/2013 Go to the issue

Topic paper

Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact

Original Article

Long-term angiogenic activity of free grafts and pedicle flap in a rabbit urethroplasty model

Original Article

Complications of kidney transplantation with grafts from expanded criteria donors

Original Article

Dhat syndrome, an emergent condition within urology in Spain

Topic Paper

Orchialgia and the chronic pelvic pain syndrome

Original Article

Poor early graft function impairs long-term outcome in living donor kidney transplantation